AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02271464
Drug: Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~* BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks),~* CAPECITABINE 500 mg/tid orally, continuously,~* CYCLOPHOSPHAMIDE 50 mg/day orally, continuously.
Trial: NCT00971802
Drug: PF-03882845 or Placebo
RxNorm normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-03882845 20 mg or Placebo, daily for 10 days.
Trial: NCT00657943
Drug: insulin aspart + insulin aspart protamin
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: insulin as requested
Trial: NCT00657943
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: insulin as requested
Trial: NCT00783133
Drug: Desloratadine 5 mg
RxNorm normalized name: desloratadine 5 MG
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarinex 5 mg daily x 7 days
Trial: NCT00783133
Drug: fexofenadine
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allegra 180 mg daily x 7 days
Trial: NCT00971802
Drug: PF-03882845 or Placebo
RxNorm normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-03882845 60 mg or Placebo, daily for 10 days.
Trial: NCT00971802
Drug: PF-03882845 or Placebo
RxNorm normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-03882845 120 mg or Placebo, daily for 10 days.
Trial: NCT00971802
Drug: PF-03882845 or Placebo
RxNorm normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-03882845 185 mg or Placebo, daily for 10 days.
Trial: NCT02218684
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02218684
Drug: Lacidipine
RxNorm normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01994642
Drug: Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02767271
Drug: Luliconazole Cream 1%
DrugBank: Luliconazole (DB08933)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Luliconazole cream will be applied topically per schedule specified in the arms.
Trial: NCT01059890
Drug: cefotaxime
RxNorm normalized name: Cefotaxime
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00027625
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00027625
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02928315
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients in the study group will receive 10 mmol of magnesium sulphate (2.47 gm). Five ampoules of 500 mg of magnesium sulphate will be dissolved in 100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
Trial: NCT04540965
Drug: Telaglenastat
RxNorm normalized name: Telaglenastat
DrugBank: Telaglenastat (DB15232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutaminase inhibitor
Trial: NCT04540965
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine-H2 Receptor Antagonist
Trial: NCT04540965
Drug: Placebo for famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo for Histamine-H2 Receptor Antagonist
Trial: NCT00706446
Drug: tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tiotropium bromide one inhalation a day for one year, along with inhaled steroids at variable dosing based on patient's prior inhaled steroid dosing and treating physician's judgement.
Trial: NCT00706446
Drug: Salmeterol
RxNorm normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: salmeterol diskus 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
Trial: NCT00706446
Drug: Formoterol
RxNorm normalized name: Formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: formoterol aerolizer 12 mcg 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
Trial: NCT00706446
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Either fluticasone propionate diskus 100 mcg 1 puff twice a day or fluticasone propionate aersol in 44 mcg, 110 mcg, 2 puffs twice a day OR fluticasone propionate 220 mcg 2 puffs once a day for one year, depending on which dose the patient was on before the start of the trial.
Trial: NCT00706446
Drug: budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Either budesonide 90 mcg 2 puffs twice a day or 180 mcg 2 puffs twice a day for one year, depending on which dose the patient was on before the start of the trial.
Trial: NCT01059890
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01059890
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01059890
Drug: Fosfocine
RxNorm normalized name: Fosfocina
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00088530
Drug: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Day 1: pixantrone (150 mg/m2), cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
Trial: NCT00088530
Drug: Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Day 1: cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
Trial: NCT03192826
Drug: Brinzolamide/Brimonidine FC
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
Trial: NCT03192826
Drug: Brimonidine 0.2%
RxNorm normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
Trial: NCT03192826
Drug: Artificial tears
RxNorm normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
Trial: NCT04610047
Drug: Norketotifen
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT01141712
Drug: BCNU
RxNorm normalized name: BCNU
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive BCNU 300 mg/m\^2 Day -6
Trial: NCT01141712
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Etoposide 100 mg/m\^2 BID Days -5 to -2
Trial: NCT01141712
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Cytarabine 100 mg/m\^2 BID Days -5 to -2
Trial: NCT01141712
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Melphalan 140 mg/m\^2 Day -1
Trial: NCT03739710
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered.
Trial: NCT03739710
Drug: Feladilimab
RxNorm normalized name: Feladilimab
DrugBank: Feladilimab (DB16415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feladilimab will be administered.
Trial: NCT03739710
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab will be administered.
Trial: NCT03739710
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab will be administered.
Trial: NCT03739710
Drug: GSK6097608
RxNorm normalized name: Immunoglobulin G1, anti-(human CD96 antigen) (human monoclonal GSK6097608 γ1-chain), disulfide with human monoclonal GSK6097608 κ-chain, dimer
DrugBank: Nelistotug (DB19334)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK6097608 will be administered.
Trial: NCT01091831
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide will be given orally at the dose of 25 mg/d for 21 days followed by a 7 days rest period (day 22 to 28)for 6 cycles every 28 days
Trial: NCT01091831
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 for 6 cycles every 28 days
Trial: NCT01091831
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan will be given iv at the dose of 200 mg/m2 for 1 day followed by stem cell support. The second MEL200 was performed 120 days after the first if ≤ PR was achieved after the 1st MEL200.
Trial: NCT04045327
Drug: Normal saline + Standard Treatment
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
Trial: NCT04045327
Drug: Centhaquine + Standard Treatment
DrugBank: Centhaquine (DB16122)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
Trial: NCT00959699
Drug: PegIFN-2b
RxNorm normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PegIFN-2b (1.5 μg/kg/week subcutaneously)
Trial: NCT00959699
Drug: RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
Trial: NCT00959699
Drug: Placebo to Boceprevir
DrugBank: Boceprevir (DB08873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo to boceprevir (orally, three times per day)
Trial: NCT00959699
Drug: Boceprevir
RxNorm normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Boceprevir (800 mg, orally, three times per day)
Trial: NCT04215536
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin dispensing claim is exposure
Trial: NCT04215536
Drug: DPP-4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP4 inhibitor dispensing claim is reference
Trial: NCT02433795
Drug: bendamustine plus rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle
Trial: NCT01398371
Drug: Withdrawal of digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants currently receiving digoxin for heart failure will have their digoxin stopped for 12 weeks.
Trial: NCT01398371
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stable digoxin therapy which produces a digoxin plasma level of 0.4-0.8.
Trial: NCT00775996
Drug: Clorazepate Dipotassium 15mg Tablets
RxNorm normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02798250
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).
Trial: NCT02798250
Drug: Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
Trial: NCT03218384
Drug: Ferric Carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Ferric Carboxymaltose 750 mg mixed under sterile conditions in 100 ml of normal saline for final concentration of 7.5 mg/ml and administered via volumetric infusion pump over 15 minutes.
Trial: NCT05016440
Drug: Lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg Lisinopril daily for 6-8 weeks postpartum
Trial: NCT01240941
Drug: MK-2206
RxNorm normalized name: MK-2206
DrugBank: MK-2206 (DB16828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose to be determined on the Phase 1b trial (listed under a separate NCT number)
Trial: NCT01240941
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg orally daily
Trial: NCT01240941
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3.6 mg orally monthly
Trial: NCT03031262
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
Trial: NCT03031262
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Chidamide at a dose of 20mg/d twice a week for 3 months.
Trial: NCT03484585
Drug: Rogaratinib (BAY1163877)
RxNorm normalized name: Rogaratinib
DrugBank: Rogaratinib (DB15078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, intake orally, 200 mg
Trial: NCT01976910
Drug: DM-CHOC-PEN
RxNorm normalized name: DM-CHOC-PEN
DrugBank: Mipicoledine (DB15075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued.
Trial: NCT04228445
Drug: 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
Trial: NCT00161733
Drug: Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D)
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00161733
Drug: TISSEEL VH fibrin sealant
RxNorm normalized name: thrombin
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02513238
Drug: Mesenchymal stem cell
RxNorm normalized name: Human mesenchymal stem cell
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stemcells injected into submandibularis
Trial: NCT01486550
Drug: Voluven (Hydroxyethyl starch 130/0,4)
RxNorm normalized name: hydroxyethyl starch 130-0.4 Injection [Voluven]
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7,5 ml/kg in the first hour and then 5 ml/kg minimum
Trial: NCT01486550
Drug: Sodium Chloride 9mg/ml
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7,5 ml/kg in the first hour and then 5 ml/kg
Trial: NCT04608955
Drug: Bedaquiline
RxNorm normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This licensed drug will be used in arm F as positive comparator.
Trial: NCT02422394
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00354640
Drug: anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 milligram tablet PO QD for 14 days
Trial: NCT00360412
Drug: E2007
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01041313
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.
Trial: NCT01065038
Drug: Anagrelide
RxNorm normalized name: anagrelide
DrugBank: Anagrelide (DB00261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01065038
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00999544
Drug: Aprepitant 0mg
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 0mg, p.o. pretreatment
Trial: NCT00999544
Drug: Aprepitant 40mg
RxNorm normalized name: APREPITANT 40MG CAP
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 40mg, p.o. pretreatment
Trial: NCT00999544
Drug: Aprepitant 200mg
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 200mg, p.o. pretreatment
Trial: NCT00999544
Drug: Oxycodone 0mg, p.o.
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone 0mg, p.o.
Trial: NCT00999544
Drug: Oxycodone 20mg, p.o.
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone 20mg, p.o.
Trial: NCT00999544
Drug: Oxycodone 40mg, p.o.
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone 40mg, p.o.
Trial: NCT00999544
Drug: Oxycodone 0mg, IN
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone 0mg, IN
Trial: NCT00999544
Drug: Oxycodone 15mg, IN
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone 15mg, IN
Trial: NCT00999544
Drug: Oxycodone 30mg, IN
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone 30mg, IN
Trial: NCT01594931
Drug: pyronaridine/artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1. The tablets were taken daily for 3 days.
Trial: NCT03625960
Drug: Cantharidin
RxNorm normalized name: cantharidin
DrugBank: Cantharidin (DB12328)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A thin film of cantharidin is applied to the surface of the wart and to 1 millimeter area surrounding the wart. After the film dries, it is covered with an occlusive dressing for 24 hours. The patient removes the area the next day and thoroughly washes the area with soap and water. Patients return to clinic a week later.
Trial: NCT01379560
Drug: unoprostone isopropyl
RxNorm normalized name: Unoprostone Isopropyl
DrugBank: Propyl acetate (DB01670)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. unoprostone isopropyl (2 drops)~2. placebo (2 drops)
Trial: NCT01379560
Drug: unoprostone isopropyl
RxNorm normalized name: Unoprostone Isopropyl
DrugBank: Propyl acetate (DB01670)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. unoprostone isopropyl (3 drops)~2. placebo (3 drops)
Trial: NCT01751360
Drug: SYR-472
RxNorm normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03924427
Drug: BMS-986165
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablet administration
Trial: NCT02897076
Drug: betamethasone 24 mg
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no